COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01158079
Recruitment Status : Completed
First Posted : July 8, 2010
Last Update Posted : October 12, 2012
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Brief Summary:
This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: ALN-VSP02 Phase 1

Detailed Description:
Study ALN-VSP02 is an extension study for previously conducted ALN-VSP02 studies. The study is being conducted to allow for continued ALN-VSP02 therapy for patients who completed participation in an ALN-VSP02 clinical study, achieved clinical benefit with ALN-VSP02 (i.e., disease response of stable disease or better), and, in the Investigator's opinion, may benefit from continuation of ALN-VSP02 therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Open-Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
Study Start Date : July 2010
Actual Primary Completion Date : August 2012
Actual Study Completion Date : September 2012

Intervention Details:
  • Drug: ALN-VSP02
    The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study

Primary Outcome Measures :
  1. Collect long term ALN-VSP02 safety data [ Time Frame: Throughout the study ]
    Patients remain on treatment until disease progression or an adverse event. Adverse events are assessed throughout treatment.

Secondary Outcome Measures :
  1. Assess disease response by Response Evaluation Criteria In Solid Tumors (RECIST) [ Time Frame: Every 2 months ]
    Disease response is assessed every 2 months until the patient stops treatment due to disease progression or an adverse event

  2. Evaluate preliminary evidence of antitumor activity/antiangiogenic activity [ Time Frame: Every 3 - 6 months ]
    Evaluations will take place every 3-6 months until disease progression

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient has completed a previous ALN-VSP02 study, and is deemed to have stable disease or better.
  2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  3. Patient has adequate hematologic, liver, and renal function.

Exclusion Criteria:

  1. Patient is receiving full-dose (therapeutic) anticoagulation therapy and/or aspirin > 325 mg/day or other platelet inhibitory agents.
  2. Patient has clinically significant cardiovascular disease or uncontrolled serious cardiac arrhythmia.
  3. Patient has clinically significant cerebrovascular disease.
  4. Patient has a seizure disorder not controlled on medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01158079

Layout table for location information
United States, Arizona
TGen Clinical Research Service at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Center
Detroit, Michigan, United States, 48201
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Hospital Virgen del Rocio
Seville, Andalucia, Spain, 41013
Hospital Universitario Vall d'Hebron
Barcelona, Catalonia, Spain, 08035
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Sponsors and Collaborators
Alnylam Pharmaceuticals
Layout table for investigator information
Study Director: Akshay Vaishnaw, MD PhD Alnylam Pharmaceuticals
Layout table for additonal information
Responsible Party: Alnylam Pharmaceuticals Identifier: NCT01158079    
Other Study ID Numbers: ALN-VSP02-002
First Posted: July 8, 2010    Key Record Dates
Last Update Posted: October 12, 2012
Last Verified: October 2012
Keywords provided by Alnylam Pharmaceuticals:
Solid Tumors
Advanced Solid Tumors with Liver Involvement